Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norbert Vey

Showing results (11-20 of 251) with videos related to

Pageof 26
Sort By:
Experimental Hematology|November 21, 2017
T-cell-replete haploidentical transplantation in acute myeloid leukemiaLuca Castagna, Raynier Devillier, Norbert Vey, et al.
Haematologica|May 10, 2007
Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemiaDidier Blaise, Norbert Vey, Catherine Faucher, et al.
Cancer Drug Resistance (Alhambra, Calif.)|April 17, 2023
Targeting regulated cell death pathways in acute myeloid leukemiaSylvain Garciaz, Thomas Miller, Yves Collette, et al.
Oncoimmunology|December 25, 2012
Immunotherapy of acute myeloid leukemia based on γδ T cellsJulie Gertner-Dardenne, Cyril Fauriat, Norbert Vey, et al.
British Journal of Cancer|October 11, 2017
Targeting apoptosis in acute myeloid leukaemiaPhilippe A Cassier, Marie Castets, Amine Belhabri, et al.
Cancers|March 28, 2024
Venetoclax Resistance in Acute Myeloid LeukemiaSylvain Garciaz, Marie-Anne Hospital, Yves Collette, et al.
Expert Opinion on Investigational Drugs|January 26, 2016
Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromesMaximilian Stahl, Steven D Gore, Norbert Vey, et al.
Trends in Molecular Medicine|June 3, 2009
Natural killer and gammadelta T cells in haematological malignancies: enhancing the immune effectorsJérôme Rey, Caroline Veuillen, Norbert Vey, et al.
Cancers|November 27, 2021
Venetoclax in Acute Myeloid Leukemia: Molecular Basis, Evidences for Preclinical and Clinical Efficacy and Strategies to Target ResistanceSylvain Garciaz, Colombe Saillard, Yosr Hicheri, et al.
Health Expectations : an International Journal of Public Participation in Health Care and Health Policy|April 20, 2012
Contributing to research via biobanks: what it means to cancer patientsIsabelle Pellegrini, Christian Chabannon, Julien Mancini, et al.
Pageof 26

Showing results (11-20 of 251) with videos related to

Sort By:
Pageof 26
Experimental Hematology|November 21, 2017
T-cell-replete haploidentical transplantation in acute myeloid leukemiaLuca Castagna, Raynier Devillier, Norbert Vey, et al.
Haematologica|May 10, 2007
Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemiaDidier Blaise, Norbert Vey, Catherine Faucher, et al.
Cancer Drug Resistance (Alhambra, Calif.)|April 17, 2023
Targeting regulated cell death pathways in acute myeloid leukemiaSylvain Garciaz, Thomas Miller, Yves Collette, et al.
Oncoimmunology|December 25, 2012
Immunotherapy of acute myeloid leukemia based on γδ T cellsJulie Gertner-Dardenne, Cyril Fauriat, Norbert Vey, et al.
British Journal of Cancer|October 11, 2017
Targeting apoptosis in acute myeloid leukaemiaPhilippe A Cassier, Marie Castets, Amine Belhabri, et al.
Cancers|March 28, 2024
Venetoclax Resistance in Acute Myeloid LeukemiaSylvain Garciaz, Marie-Anne Hospital, Yves Collette, et al.
Expert Opinion on Investigational Drugs|January 26, 2016
Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromesMaximilian Stahl, Steven D Gore, Norbert Vey, et al.
Trends in Molecular Medicine|June 3, 2009
Natural killer and gammadelta T cells in haematological malignancies: enhancing the immune effectorsJérôme Rey, Caroline Veuillen, Norbert Vey, et al.
Cancers|November 27, 2021
Venetoclax in Acute Myeloid Leukemia: Molecular Basis, Evidences for Preclinical and Clinical Efficacy and Strategies to Target ResistanceSylvain Garciaz, Colombe Saillard, Yosr Hicheri, et al.
Health Expectations : an International Journal of Public Participation in Health Care and Health Policy|April 20, 2012
Contributing to research via biobanks: what it means to cancer patientsIsabelle Pellegrini, Christian Chabannon, Julien Mancini, et al.
Pageof 26